URGN
UroGen Pharma Ltd.
Biotechnology
Market Cap$1.29B
5Y Perf.+13.3%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
URGN vs PAHC
Revenue, margins, valuation, and 5-year total return — side by side.
PAHC
Phibro Animal Health Corporation
Drug Manufacturers - Specialty & Generic
Market Cap$1.75B
5Y Perf.+64.7%
URGN vs PAHC — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | URGN | PAHC |
|---|---|---|
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
| Market Cap | $1.29B | $1.75B |
| Revenue (TTM) | $140M | $1.46B |
| Net Income (TTM) | $-133M | $92M |
| Gross Margin | 89.9% | 31.9% |
| Operating Margin | -77.0% | 11.6% |
| Forward P/E | — | 14.2x |
| Total Debt | $128M | $762M |
| Cash & Equiv. | $111M | $68M |
URGN vs PAHC — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
URGN
PAHC
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | 100 | 113.3 | +13.3% |
| Phibro Animal Healt… (PAHC) | 100 | 164.7 | +64.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: URGN vs PAHC
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: PAHC leads in 5 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. UroGen Pharma Ltd. is the stronger pick specifically for recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
URGN
UroGen Pharma Ltd.
The Momentum Pick
URGN is the clearest fit if your priority is momentum.
- +162.7% vs PAHC's +125.1%
Best for: momentum
PAHC
Phibro Animal Health Corporation
The Income Pick
PAHC carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 0 yrs, beta 1.38, yield 1.1%
- Rev growth 27.4%, EPS growth 18.8%, 3Y rev CAGR 11.2%
- 128.6% 10Y total return vs URGN's 90.2%
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | PAHC | 27.4% revenue growth vs URGN's 21.4% |
| Quality / Margins | PAHC | 6.3% margin vs URGN's -94.8% |
| Stability / Safety | PAHC | Beta 1.38 vs URGN's 1.88 |
| Dividends | PAHC | 1.1% yield; the other pay no meaningful dividend |
| Momentum (1Y) | URGN | +162.7% vs PAHC's +125.1% |
| Efficiency (ROA) | PAHC | 6.7% ROA vs URGN's -62.8% |
URGN vs PAHC — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
URGN vs PAHC — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLPAHCLAGGINGURGN
URGNUroGen Pharma Ltd.
0leads
PAHCPhibro Animal Health …
3leads
6 Total Categories
CATEGORYLEADERvs URGNMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
PAHC4/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
PAHC4/6
Total Returns1Y, 3Y, 5Y total returns with dividends
PAHC4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
PAHC leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
PAHC is the larger business by revenue, generating $1.5B annually — 10.4x URGN's $140M. PAHC is the more profitable business, keeping 6.3% of every revenue dollar as net income compared to URGN's -94.8%. On growth, URGN holds the edge at +151.6% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | URGNUroGen Pharma Ltd. | PAHCPhibro Animal Hea… |
|---|---|---|
| RevenueTrailing 12 months | $140M | $1.5B |
| EBITDAEarnings before interest/tax | -$106M | $220M |
| Net IncomeAfter-tax profit | -$133M | $92M |
| Free Cash FlowCash after capex | -$166M | $47M |
| Gross MarginGross profit ÷ Revenue | +89.9% | +31.9% |
| Operating MarginEBIT ÷ Revenue | -77.0% | +11.6% |
| Net MarginNet income ÷ Revenue | -94.8% | +6.3% |
| FCF MarginFCF ÷ Revenue | -118.2% | +3.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +151.6% | +20.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +48.9% | +7.4% |
PAHC leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
Evenly matched — URGN and PAHC each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | URGNUroGen Pharma Ltd. | PAHCPhibro Animal Hea… |
|---|---|---|
| Market CapShares × price | $1.3B | $1.7B |
| Enterprise ValueMkt cap + debt − cash | $1.3B | $2.4B |
| Trailing P/EPrice ÷ TTM EPS | -8.34x | 36.27x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 14.23x |
| PEG RatioP/E ÷ EPS growth rate | — | 4.85x |
| EV / EBITDAEnterprise value multiple | — | 15.65x |
| Price / SalesMarket cap ÷ Revenue | 11.79x | 1.35x |
| Price / BookPrice ÷ Book value/share | — | 6.15x |
| Price / FCFMarket cap ÷ FCF | — | 41.82x |
Evenly matched — URGN and PAHC each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
PAHC leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), PAHC scores 5/9 vs URGN's 1/9, reflecting solid financial health.
| Metric | URGNUroGen Pharma Ltd. | PAHCPhibro Animal Hea… |
|---|---|---|
| ROE (TTM)Return on equity | — | +30.8% |
| ROA (TTM)Return on assets | -62.8% | +6.7% |
| ROICReturn on invested capital | — | +9.8% |
| ROCEReturn on capital employed | -63.4% | +12.0% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 5 |
| Debt / EquityFinancial leverage | — | 2.67x |
| Net DebtTotal debt minus cash | $18M | $694M |
| Cash & Equiv.Liquid assets | $111M | $68M |
| Total DebtShort + long-term debt | $128M | $762M |
| Interest CoverageEBIT ÷ Interest expense | -3.86x | 3.64x |
PAHC leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
PAHC leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in PAHC five years ago would be worth $16,597 today (with dividends reinvested), compared to $14,594 for URGN. Over the past 12 months, URGN leads with a +162.7% total return vs PAHC's +125.1%. The 3-year compound annual growth rate (CAGR) favors PAHC at 45.9% vs URGN's 28.9% — a key indicator of consistent wealth creation.
| Metric | URGNUroGen Pharma Ltd. | PAHCPhibro Animal Hea… |
|---|---|---|
| YTD ReturnYear-to-date | +17.1% | +16.0% |
| 1-Year ReturnPast 12 months | +162.7% | +125.1% |
| 3-Year ReturnCumulative with dividends | +114.3% | +210.4% |
| 5-Year ReturnCumulative with dividends | +45.9% | +66.0% |
| 10-Year ReturnCumulative with dividends | +90.2% | +128.6% |
| CAGR (3Y)Annualised 3-year return | +28.9% | +45.9% |
PAHC leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — URGN and PAHC each lead in 1 of 2 comparable metrics.
Risk & Volatility
PAHC is the less volatile stock with a 1.38 beta — it tends to amplify market swings less than URGN's 1.88 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. URGN currently trades 88.6% from its 52-week high vs PAHC's 71.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | URGNUroGen Pharma Ltd. | PAHCPhibro Animal Hea… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.88x | 1.38x |
| 52-Week HighHighest price in past year | $30.00 | $60.08 |
| 52-Week LowLowest price in past year | $3.42 | $19.00 |
| % of 52W HighCurrent price vs 52-week peak | +88.6% | +71.8% |
| RSI (14)Momentum oscillator 0–100 | 67.7 | 60.3 |
| Avg Volume (50D)Average daily shares traded | 863K | 302K |
Evenly matched — URGN and PAHC each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates URGN as "Buy" and PAHC as "Buy". Consensus price targets imply 50.4% upside for URGN (target: $40) vs 13.5% for PAHC (target: $49). PAHC is the only dividend payer here at 1.11% yield — a key consideration for income-focused portfolios.
| Metric | URGNUroGen Pharma Ltd. | PAHCPhibro Animal Hea… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $40.00 | $49.00 |
| # AnalystsCovering analysts | 15 | 13 |
| Dividend YieldAnnual dividend ÷ price | — | +1.1% |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | $0.48 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
PAHC leads in 3 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 2 categories are tied.
Best OverallPhibro Animal Health Corpor… (PAHC)Leads 3 of 6 categories
Loading custom metrics...
URGN vs PAHC: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is URGN or PAHC a better buy right now?
For growth investors, Phibro Animal Health Corporation (PAHC) is the stronger pick with 27.
4% revenue growth year-over-year, versus 21. 4% for UroGen Pharma Ltd. (URGN). Phibro Animal Health Corporation (PAHC) offers the better valuation at 36. 3x trailing P/E (14. 2x forward), making it the more compelling value choice. Analysts rate UroGen Pharma Ltd. (URGN) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — URGN or PAHC?
Over the past 5 years, Phibro Animal Health Corporation (PAHC) delivered a total return of +66.
0%, compared to +45. 9% for UroGen Pharma Ltd. (URGN). Over 10 years, the gap is even starker: PAHC returned +128. 6% versus URGN's +90. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — URGN or PAHC?
By beta (market sensitivity over 5 years), Phibro Animal Health Corporation (PAHC) is the lower-risk stock at 1.
38β versus UroGen Pharma Ltd. 's 1. 88β — meaning URGN is approximately 37% more volatile than PAHC relative to the S&P 500.
04Which is growing faster — URGN or PAHC?
By revenue growth (latest reported year), Phibro Animal Health Corporation (PAHC) is pulling ahead at 27.
4% versus 21. 4% for UroGen Pharma Ltd. (URGN). On earnings-per-share growth, the picture is similar: Phibro Animal Health Corporation grew EPS 1883% year-over-year, compared to -7. 8% for UroGen Pharma Ltd.. Over a 3-year CAGR, URGN leads at 19. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — URGN or PAHC?
Phibro Animal Health Corporation (PAHC) is the more profitable company, earning 3.
7% net margin versus -139. 8% for UroGen Pharma Ltd. — meaning it keeps 3. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PAHC leads at 8. 5% versus -113. 7% for URGN. At the gross margin level — before operating expenses — URGN leads at 88. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is URGN or PAHC more undervalued right now?
Analyst consensus price targets imply the most upside for URGN: 50.
4% to $40. 00.
07Which pays a better dividend — URGN or PAHC?
In this comparison, PAHC (1.
1% yield) pays a dividend. URGN does not pay a meaningful dividend and should not be held primarily for income.
08Is URGN or PAHC better for a retirement portfolio?
For long-horizon retirement investors, Phibro Animal Health Corporation (PAHC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (1.
1% yield, +128. 6% 10Y return). UroGen Pharma Ltd. (URGN) carries a higher beta of 1. 88 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PAHC: +128. 6%, URGN: +90. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between URGN and PAHC?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
PAHC pays a dividend while URGN does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(URGN: 151.6% · PAHC: 20.9%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.